Xilio Therapeutics (XLO) director receives 5,000 stock options at $7.99 strike

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Xilio Therapeutics director Sara Bonstein received a grant of stock options covering 5,000 shares of common stock. The options have an exercise price of $7.99 per share and expire on June 10, 2036. They vest 100% on June 11, 2027 or at the next annual stockholder meeting, whichever occurs first, assuming continued service.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Bonstein Sara

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	5,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 5,000 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Option grant size: 5,000 options Exercise price: $7.99 per share Expiration date: June 10, 2036 +3 more

6 metrics

Option grant size 5,000 options Stock Option (right to buy) granted June 11, 2026

Exercise price $7.99 per share Conversion or exercise price of stock options

Expiration date June 10, 2036 Option expiration for the 5,000-share grant

Underlying shares 5,000 shares Common stock underlying the options

Post-transaction options held 5,000 options Total derivative holdings following the grant

Vesting condition 100% by earlier of June 11, 2027 or next annual meeting Subject to continued service through vesting date

Key Terms

Stock Option (right to buy), Grant, award, or other acquisition, exercise price, annual meeting of stockholders, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

exercise price financial

"conversion_or_exercise_price: "7.9900""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

annual meeting of stockholders financial

"the Issuer's next annual meeting of stockholders following the grant date"

vesting date financial

"subject to the Reporting Person's continued service to the Issuer through the vesting date"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/12/2026 - 04:07 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bonstein Sara

(Last)

(First)

(Middle)

828 WINTER STREET

SUITE 300

(Street)

WALTHAM

MASSACHUSETTS

02451

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Xilio Therapeutics, Inc. [ XLO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$7.99	06/11/2026		A		5,000		⁽¹⁾	06/10/2036	Common Stock	5,000	$0	5,000	D

Explanation of Responses:

1. The option was granted on June 11, 2026 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 11, 2027 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date.

	/s/ Christopher Frankenfield, Attorney-in-Fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Xilio Therapeutics (XLO) director Sara Bonstein report on this Form 4?

Sara Bonstein reported receiving a grant of stock options for 5,000 shares of Xilio Therapeutics common stock. The filing classifies this as a grant or award acquisition, not an open-market buy or sell transaction, and it increases her derivative holdings to 5,000 options.

What are the key terms of Sara Bonstein’s Xilio Therapeutics stock options?

The stock options cover 5,000 shares of Xilio Therapeutics common stock at a $7.99 exercise price. They were granted on June 11, 2026 and expire on June 10, 2036, giving a 10-year window to exercise once vested under the specified conditions.

When do Sara Bonstein’s Xilio Therapeutics options vest according to this Form 4?

The options vest as to 100% of the 5,000 underlying shares on the earlier of June 11, 2027 or Xilio Therapeutics’ next annual meeting of stockholders after the grant date, provided Sara Bonstein continues to serve the company through the vesting date.

Does this Xilio Therapeutics Form 4 show any stock sales or purchases by Sara Bonstein?

The Form 4 does not report any open-market stock purchases or sales. It shows only a grant of 5,000 stock options categorized as a grant, award, or other acquisition, which is a compensation-related derivative award rather than a buy or sell transaction.

How many Xilio Therapeutics options does Sara Bonstein hold after this grant?

After this transaction, Sara Bonstein is reported as directly holding 5,000 stock options in Xilio Therapeutics. These options correspond to 5,000 underlying shares of common stock and represent her derivative position shown in this filing following the grant.

What is the nature of ownership for Sara Bonstein’s Xilio Therapeutics option grant?

The filing indicates the 5,000 stock options are held directly by Sara Bonstein. The ownership code is listed as “D” for direct, and there is no footnote indicating an indirect holding through another entity or any disclaimer of beneficial ownership.